Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Targeted Medical Pharma, Inc. (OTC: TRGM).

Full DD Report for TRGM

You must become a subscriber to view this report.


Recent News from (OTC: TRGM)

Guardion Health Sciences Begins U.S. IPO Effort
Quick Take Guardion Health Sciences ( GHSI ) intends to raise gross proceeds of $10 million from a U.S. IPO, according to an S-1 registration statement . The firm provides condition-specific medical foods and vision testing solutions. GHSI is seeking public capital at a difficult time i...
Source: SeekingAlpha
Date: November, 02 2018 17:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-13N/A0.007N/AN/A0
2018-12-12N/A0.007N/AN/A0
2018-12-11N/A0.007N/AN/A0
2018-12-100.0070.0070.0070.00722,400
2018-12-070.00810.0080.00810.00819,315

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-109,80022,40043.7500Short
2018-11-1412,85013,60094.4853Short
2018-11-05351,2352.8340Cover
2018-10-2979,075134,07558.9782Short
2018-10-2411,76711,81799.5769Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TRGM.


About Targeted Medical Pharma, Inc. (OTC: TRGM)

Logo for Targeted Medical Pharma, Inc. (OTC: TRGM)

Targeted Medical Pharma, Inc. OTCQB:TRGM is a publicly traded, Los Angeles based biotechnology company that develops amino acid based medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz. The products are sold directly to physicians, pharmacies and patients in the United States. The company is currently developing amino acid based therapies designed for the oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF I. Targeted Medical Pharma and its subsidiary companies, Complete Claims Processing and Physician Therapeutics, provide healthcare practitioners and patients with clinically proven therapies required to safely and effectively manage disease without harmful side effects. We are committed to delivering long term value to investors by maintaining disciplined cost controls, optimizing capital investment and adhering to the highest standards of corporate governance.

 

 

 

Current Management

  • Kim Giffoni / CEO
    • Kim Giffoni is our Chief Executive Officer. Mr. Giffoni is a founder of the Company and has served as President, Chief Operating Officer and as a member of the board of directors of Targeted Medical Pharma. Prior to assuming his current responsibilities, from April to May , Mr. Giffoni served as president of NutraCorp Scientific, Inc., a dietary supplement manufacturer with worldwide distribution. From through , Mr. Giffoni founded and served as president of the Southern California real estate development company, Giffoni Development. Prior to that Mr. Giffoni served as an advertising manager of Herald Community Newspapers, Las Virgenes Enterprise Newspaper Group and cofounded the Malibu Surfside News Publication. Mr. Giffoni earned a Bachelor of Arts in Communications from California State University at Northridge. Mr. Giffoni is a former professional baseball player for the Kansas City Royals and is a commerciallyrated helicopter pilot. Mr. Giffoni s role as a founding member of the Company, his experience in sales and marketing and his background in business development will be a valuable asset for Targeted Medical Pharma and the company s shareholders.
  • William B. Horne / CFO
    • Mr. Horne has nearly years of combined experience as a financial executive, auditor and financial consultant. Mr. Horne previously held the position of Chief Financial Officer in various companies in the healthcare and hightech field, including OptimisCorp, from January to May , a privately held, diversified healthcare technology company located in Los Angeles, California. Mr. Horne served as the Chief Financial Officer of Patient Safety Technologies, Inc. OTCBB: PSTX , a medical device company located in Irvine, California, from June to October and as the interim Chief Executive Officer from January to April . In his dual role at Patient Safety Technologies, Mr. Horne was directly responsible for structuring the divestiture of noncore assets, capital financings and debt restructuring. Mr. Horne held the position of Managing Member amp Chief Financial Officer of Alaska Wireless Communications, LLC, a privately held, advanced cellular communications company, from its inception in May until November . Mr. Horne was responsible for negotiating the sale of Alaska Wireless to General Communication Inc. NASDAQ: GNCMA . From November to December , Mr. Horne held the position of Chief Financial Officer of The Phoenix Partners, a venture capital limited partnership located in Seattle, Washington. Mr. Horne has also held supervisory positions at Price Waterhouse, LLP and has a Bachelor of Arts Magna Cum Laude in Accounting from Seattle University.
  • David Silver / Chief Med. Officer
    • Dr. Silver currently serves as Chief Medical Officer and formerly held the positions of President and Chief Operating Officer at Targeted Medical Pharma. Dr. Silver is a practicing board certified rheumatologist and internist with privileges at CedarsSinai Medical Center in Los Angeles, California and served as clinical chief of rheumatology at Cedars Sinai from October to September . Since June , Dr. Silver has taught at the University of California at Los Angeles School of Medicine in various capacities and in July was named an associate clinical professor. From December to October , Dr. Silver served as the director of the Chronic Pain Rehabilitation Program at CedarsSinai Medical Center and, since January , Dr. Silver has served as associate medical director of the Osteoporosis Medical Center, a nonprofit research corporation in Beverly Hills, California. From May to April , Dr. Silver served as member of the scientific advisory committee of the American College of Rheumatology and, from May to April , he served as a member of the awards and grants committee. Dr. Silver has written a book entitled Playing Through Arthritis: How to Conquer Pain and Enjoy Your Favorite Sports and Activities. Dr. Silver has also been granted several research grants to study osteoarthritis, osteoporosis, fibromyalgia, rheumatoid arthritis and epicondylitis. Dr. Silver is the author of numerous publications in peerreviewed journals and has regularly accepted speaking engagements on various topics in rheumatology. Dr. Silver also serves as peer reviewer for Arthritis and Rheumatism, Clinical Rheumatology, Osteoporosis International, Journal of Osteoporosis and American Journal of Managed Care.
  • Kerry Weems / Chairman
    • Kerry Weems is the Chief Executive Officer of TwinMed, LLC. Mr. Weems previously served as Vice President and General Manager of Health Solutions Sector at General Dynamics Information Technology and Senior Vice President for Health Solutions at Vangent Corporation. While there, he provided executive leadership to more than , health and health IT professionals providing solutions in fraud detection and prevention, quality and pay for performance, system and infrastructure modernization, and data analytics. Mr. Weems had a year career with the federal government and served as an Administrator of the Centers for Medicare and Medicaid Services and Vice Chairman of the American Health Information Community, where he implemented the Medicare eprescribing program, began pilot projects for electronic health records and personal health records, and instituted a number of landmark payment reforms, including nonpayment for certain medical errors. Mr. Weems served in a number of senior positions at the Department of Health and Human Services, including Deputy Chief of Staff, Chief Financial Officer and Chief Budget Officer, where he oversaw a budget exceeding billion. While at HHS, he led the implementation of the largest and most successful automated financial management system in government, the Unified Financial Management System. Mr. Weems served both Republican and Democratic administrations and received the highest award for civilian employees, the Presidential Rank award from both Presidents Clinton and Bush. Mr. Weems has a Masters of Business Administration degree from the University of New Mexico and Bachelor degrees in Philosophy and Management from New Mexico State University.
  • Maurice J. DeWald / Maurice J. Dewald has served as a director since February . Since June , Mr. DeWald has served as the chairman and chief executive officer of Verity Financial Group, Inc., a financial advisory firm with a primary focus on the healthcare and technology sectors. Mr. DeWald also serves as a director of Mizuho Corporate Bank of California, as nonexecutive Chairman of Integrated Healthcare Holdings, Inc. and Healthcare Trust of America, Inc. Mr. DeWald also previously served as a director of Tenet Healthcare Corporation, ARV Assisted Living, Inc. and Quality Systems, Inc. From to , Mr. DeWald worked with the international accounting and auditing firm of KPMG, LLP, where he served at various times as an audit partner, a member of the board of directors and managing partner of the Orange County, California, Los Angeles, California and Chicago offices. Mr. DeWald has served as chairman and director of both the United Way of Greater Los Angeles and the United Way of Orange County California. Mr. DeWald holds a Bachelor of Arts degree in Accounting and Finance from the University of Notre Dame and is a member of its Mendoza School of Business Advisory Council. Mr. DeWald is a Certified Public Accountant inactive , and is a member of the California Society of Certified Public Accountants and the American Institute of Certified Public Accountants. Mr. DeWald s experience as a director of companies focused on health care, which familiarized him with the regulatory framework within which we work, as a financial advisor to the healthcare industry as well as his education and experience in accounting leads us to conclude that he would make significant contributions as a director.
  • Kim Giffoni / Kim Giffoni is our Chief Executive Officer. Mr. Giffoni is a founder of the Company and has served as President, Chief Operating Officer and as a member of the board of directors of Targeted Medical Pharma. Prior to assuming his current responsibilities, from April to May , Mr. Giffoni served as president of NutraCorp Scientific, Inc., a dietary supplement manufacturer with worldwide distribution. From through , Mr. Giffoni founded and served as president of the Southern California real estate development company, Giffoni Development. Prior to that Mr. Giffoni served as an advertising manager of Herald Community Newspapers, Las Virgenes Enterprise Newspaper Group and cofounded the Malibu Surfside News Publication. Mr. Giffoni earned a Bachelor of Arts in Communications from California State University at Northridge. Mr. Giffoni is a former professional baseball player for the Kansas City Royals and is a commerciallyrated helicopter pilot. Mr. Giffoni s role as a founding member of the Company, his experience in sales and marketing and his background in business development will be a valuable asset for Targeted Medical Pharma and the company s shareholders.
  • David Silver / Dr. Silver currently serves as Chief Medical Officer and formerly held the positions of President and Chief Operating Officer at Targeted Medical Pharma. Dr. Silver is a practicing board certified rheumatologist and internist with privileges at CedarsSinai Medical Center in Los Angeles, California and served as clinical chief of rheumatology at Cedars Sinai from October to September . Since June , Dr. Silver has taught at the University of California at Los Angeles School of Medicine in various capacities and in July was named an associate clinical professor. From December to October , Dr. Silver served as the director of the Chronic Pain Rehabilitation Program at CedarsSinai Medical Center and, since January , Dr. Silver has served as associate medical director of the Osteoporosis Medical Center, a nonprofit research corporation in Beverly Hills, California. From May to April , Dr. Silver served as member of the scientific advisory committee of the American College of Rheumatology and, from May to April , he served as a member of the awards and grants committee. Dr. Silver has written a book entitled Playing Through Arthritis: How to Conquer Pain and Enjoy Your Favorite Sports and Activities. Dr. Silver has also been granted several research grants to study osteoarthritis, osteoporosis, fibromyalgia, rheumatoid arthritis and epicondylitis. Dr. Silver is the author of numerous publications in peerreviewed journals and has regularly accepted speaking engagements on various topics in rheumatology. Dr. Silver also serves as peer reviewer for Arthritis and Rheumatism, Clinical Rheumatology, Osteoporosis International, Journal of Osteoporosis and American Journal of Managed Care.
  • Thomas Wenkart / Dr. Thomas Wenkart attended Sydney University and graduated as a medico in . He went to Royal Newcastle Hospital and entered General Practice and the world of medical computing in . Dr. Wenkart acquired his first private hospital interest in and has since expanded Macquarie Hospital Services in Sydney and an interest in the Bega Valley Private Hospital day centre complex. Macquarie Hospital Services includes five private hospitals which cater for surgery, rehabilitation and medical services. Each hospital is undergoing significant development and expansion of their facilities. In , Dr. Wenkart established the Health Care Research Institute and the Wenkart Foundation which supports the Arts and Health Sciences with the credo of community benefits in the shortest possible time. In the Wenkart Foundation established the Wenkart Chair of the Endothelium at Sydney University and the Centenary Institute. Dr. Wenkart s medicopolitical interests included many years of involvement in the AMA system as an officebearer and also likewise in the private hospital sector in the s and s. He also completed his MPH at Sydney University in the s. Over the years support and active participation in the Arts has been diverse and includes Musica Viva, Opera Foundation Australia, Sydney Eisteddfod, Opera and Arts Foundation and more recently the Sydney Conservatorium of Music. Support and promotion of Australian talent overseas and specifically Europe, is a current endeavor. Dr. Wenkart s most recent endeavor involves electronic medical records. He firmly believes that the future for Electronic Medical Records are Personal Health Records controlled by individuals as a lifelong health record.

Current Share Structure

  • Market Cap: $310,579 - 03/09/2018
  • Authorized: 100,000,000 - 11/03/2017
  • Issue and Outstanding: 27,730,227 - 11/03/2017

 


Recent Filings from (OTC: TRGM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 12 2017

 

 


Daily Technical Chart for (OTC: TRGM)

Daily Technical Chart for (OTC: TRGM)


Stay tuned for daily updates and more on (OTC: TRGM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TRGM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TRGM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TRGM and does not buy, sell, or trade any shares of TRGM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/